Hafslund Nycomed has filed Product License Applications in the UK, Ireland and Denmark for a new nonsteroidal anti-inflammatory drug, Safem (lornoxicam), as a treatment for arthritis and other rheumatic diseases. The product is also an effective, non-habit-forming preparation for the treatment of moderate to severe pain, according to the company.
Safem was developed by Nycomed's wholly-owned Austrian subsidiary, HN Pharma, in collaboration with research units in Denmark, Norway and other countries. The product has been licensed out to development partners in Germany, Italy and Japan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze